| 恩替卡韦治疗慢性乙型肝炎的研究现状 |
| |
| 引用本文： | 吕莹,张占卿.恩替卡韦治疗慢性乙型肝炎的研究现状[J].世界感染杂志,2007,7(2):153-156. |
| |
| 作者姓名： | 吕莹 张占卿 |
| |
| 作者单位： | 上海市(复旦大学附属)公共卫生临床中心,上海,201508;上海市(复旦大学附属)公共卫生临床中心,上海,201508 |
| |
| 摘 要： | 对恩替卡韦的药理学研究和临床试验结果进行了简要回顾。恩替卡韦可使未接受过核苷／酐类似物和拉米夫定抵抗的慢性乙型肝炎病人的肝脏组织学、血清病毒学和血清生化学得到改善。治疗剂量的思替卡韦有很少且轻微的不良反应。
|
| 关 键 词： | 恩替卡韦 临床试验 不良反应 药物抵抗 |
| 文章编号： | 1562-3122（2007）02-0153-04 |
| 收稿时间： | 2006-11-06 |
| 修稿时间： | 2006-12-09 |
Status quo of treating chronic hepatitis B with entecavir |
| |
| LV Ying, ZHANG Zhanqing public health center, Shanghai, China.Status quo of treating chronic hepatitis B with entecavir[J].World Journal of Infection,2007,7(2):153-156. |
| |
| Authors: | LV Ying ZHANG Zhanqing public health center Shanghai China |
| |
| Institution: | LV Ying, ZHANG Zhanqing public health center, Shanghai, 201508, China) |
| |
| Abstract: | The results of pharmacological and clinical study of entecavir are reviewed briefly. Entecavir can improve the profiles of hepatic histology, serum virology and serum biochemistry for nucleotide/nucleoside-naive and lamivudine-resistant patients with chronic hepatitis B. Entecavir in therapeutical dose has few and mild adverse reaction. |
| |
| Keywords: | entecavir clinical study adverse reaction drug-resistance |
| 本文献已被 维普 万方数据 等数据库收录！ |
